All Patents articles – Page 3
-
BusinessCholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation
-
NewsPatent backlogs cost the world millions, IP experts warn
Estimates put a $10bn price tag on every year of delays
-
NewsPfizer launches new biosimilar drug in US
Autoimmune disease treatment becomes only the second biosimilar to be approved by the FDA
-
BusinessSanofi sues Merck & Co over biosimilars
Merck challenges insulin patents, but Sanofi claims infringement
-
BusinessOn the innovation horizon
Bringing disruptive technology to market requires enhanced collaboration
-
BusinessBrexit uncertainty ripples across regulation
What might leaving the EU mean for medicines regulation, the Unified Patent Court, and the UK’s participation in Reach?
-
BusinessHarvard settles with ex-student over drug royalties
Student claimed university forced him to accept unfair cut in patent deal
-
BusinessJudge voids Merck & Co’s $200m patent claim
‘Serious misconduct’ kills case over Gilead’s hepatitis C drugs
-
BusinessAdventures of an accidental entrepreneur
India needs to break out of its colonial mindset and tap into its innovative potential, says Biocon chief Kiran Mazumdar-Shaw
-
OpinionHealing the world
Will GSK’s move towards licensing patents in developing countries, rather than rigidly defending them, improve access to medicines?
-
BusinessGilead loses to Merck & Co in hepatitis C drug dispute
US court upholds Merck’s claim to patents related to blockbuster drugs
-
Business
Illumina to sue Oxford Nanopore over patent infringement
UK firm’s use of pore proteins in DNA sequencing alleged to contravene two Illumina patents
-
Business
Lilly loses UK patent challenge
Allergan’s cancer drug generics do not infringe patents, say UK courts
-
Business
GSK fined for stalling antidepressant generics
UK Competition and Markets Authority deems pay-for-delay deal illegal and imposes £45m in fines
-
Business
Merck & Co joins hepatitis C party
New drug adds new treatment options and increases competition in premium market
-
BusinessCrispr goes commercial
Gene editing technique Crispr has shaken up genomics research and the commercial opportunities couldn’t be more evident
-
Business
FDA takes action to remove biosimilars roadblock
The US Food and Drug Administration proposes system to name biosimilar drugs
-
Business
Blast kills six at South Korean chemical plant
One further worker injured as tank explodes during welding work
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
Business
Actavis plan to thwart generics blocked
Company prevented from withdrawing original formulation of Alzheimer’s drug to force patients onto extended release version and extend patent exclusivity